Farokhzad pointed to several large-scale deployments as evidence of platform adoption, including a 20,000-sample population study with Korea University and a 10,000-sample project in collaboration with Discovery Life Sciences. He said studies of that magnitude were not previously feasible with traditional mass spectrometry proteomics approaches, which he characterized as lacking the depth and scalability needed for standardized processing of tens of thousands of samples.Chief Executive Officer Omid Farokhza ...

Core Viewpoint - EDAP TMS S.A. has appointed David Horn to its Board of Directors, effective February 11, 2026, enhancing the board's expertise in strategic growth and transformation [1][2]. Group 1: Appointment Details - David Horn brings extensive experience in capital markets and the medical device industry, having served as President and CFO of Seer, Inc. since 2023 and previously at Morgan Stanley for over 20 years [3]. - Horn will be a member of the Audit Committee and Nominations Committee, contributing to strategic planning and execution [2][3]. Group 2: Company Leadership and Strategy - The Chairman of the Board, Lance Willsey, expressed confidence in Horn's ability to support EDAP's growth strategy and enhance shareholder value [3]. - Horn emphasized the importance of EDAP's innovation in focal therapy technology and its potential to expand clinical indications [4]. Group 3: Board Changes - Glen French has stepped down from the Board of Directors effective February 10, 2026, with appreciation expressed for his contributions [4][5].

Core Insights - Seer, Inc. announced a significant genome-wide association study (GWAS) published in Nature Genetics, demonstrating the importance of mass spectrometry validation in establishing reliable drug targets and clinical biomarkers [1][10] Group 1: Study Overview - The study involved approximately 1,600 blood samples from diverse ethnic backgrounds, with a discovery cohort of 1,260 and a replication cohort of 325, utilizing Seer's Proteograph workflow [2] - A total of 5,753 proteins were detected, with 1,980 quantified in at least 80% of participants [2] Group 2: Findings and Implications - Researchers identified 364 protein quantitative trait loci (pQTLs) associated with protein abundance, with 102 replicating in the independent cohort, including 35 previously unreported signals [3] - The study highlighted that up to one-third of protein-gene associations reported by affinity-based assays do not replicate, underscoring the necessity for accuracy in proteogenomics [4][7] Group 3: Methodology and Technology - Seer's Proteograph platform employs mass spectrometry to measure proteins directly at the peptide level, mitigating confounding effects from affinity reagents [5][6] - The study compared mass spectrometry results with two major affinity-based proteomics resources, confirming that mass spectrometry is crucial for reliable proteomic analysis [6] Group 4: Future Directions - The findings strengthen confidence in drug discovery and biomarker development by ensuring that selected targets reflect genuine biological signals rather than technical noise [9] - The study positions proteomics as a population-ready science, essential for supporting drug targets and biomarkers with the rigor needed for clinical impact [11]

Core Insights - RetinalGenix Technologies Inc. has partnered with Seer, Inc. to develop a platform for early detection and monitoring of systemic, neurodegenerative, and retinal diseases through advanced imaging and proteomics [1][2][4] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by integrating genetic screening, advanced imaging, and therapeutic development [6] - The company utilizes proprietary technologies such as High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™ to detect physiological changes indicative of various diseases [6] Collaboration Details - The collaboration aims to integrate RetinalGenix's non-invasive retinal imaging with Seer's advanced proteomic profiling to identify disease signatures before clinical symptoms appear [2][3] - The partnership targets critical conditions including Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases [2][3][4] - Seer will conduct research, development, and clinical validation programs to accelerate diagnostic innovation and enable broader deployment of early-detection solutions [3][4] Technological Integration - The integration of ultra-high-resolution retinal imaging with molecular biomarker analysis is intended to create comprehensive biomarker profiles for better disease monitoring and predictive modeling [4][8] - Seer's Proteograph® Product Suite is designed to provide deep, unbiased proteomic insights, overcoming limitations of traditional proteomic technologies [5] Vision and Goals - Both companies share a vision to transform early disease detection and advance personalized precision medicine through the convergence of imaging and proteomics [4][8]

Core Insights - RetinalGenix Technologies Inc. has partnered with Seer, Inc. to develop a platform for early detection and monitoring of systemic, neurodegenerative, and retinal diseases through advanced imaging and proteomics [1][2][4] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by integrating genetic screening, advanced imaging, and therapeutic development [6] - The company utilizes proprietary technologies such as High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™ to detect physiological changes indicative of various diseases [6] Collaboration Details - The collaboration aims to integrate RetinalGenix's non-invasive retinal imaging with Seer's advanced proteomic profiling to identify disease signatures before clinical symptoms appear [2][4] - The partnership targets critical conditions including Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases [2][3][4] - Seer will conduct research, development, and clinical validation programs to accelerate diagnostic innovation and enable broader deployment of early-detection solutions [3][4] Technological Integration - The integration of ultra-high-resolution retinal imaging with molecular biomarker analysis is intended to create comprehensive biomarker profiles for better disease monitoring and predictive modeling [4][8] - Seer's Proteograph Product Suite offers a robust workflow that addresses challenges faced by traditional proteomic technologies, enhancing the potential for biological insights [5] Vision for the Future - Both companies share a vision to transform early disease detection and advance personalized precision medicine through the convergence of imaging and proteomics [4][8]

分组1 - CytomX Therapeutics reported quarterly earnings of $0.27 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and showing an increase from $0.17 per share a year ago, representing an earnings surprise of 50% [1] - The company achieved revenues of $50.92 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 43.36%, compared to $41.46 million in the same quarter last year [2] - Over the last four quarters, CytomX Therapeutics has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] 分组2 - The stock has underperformed, losing about 9.9% since the beginning of the year, while the S&P 500 has declined by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $31.97 million, and for the current fiscal year, it is $0.32 on revenues of $111.42 million [7] - The Medical - Biomedical and Genetics industry, to which CytomX belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]